Classic Hodgkin Lymphoma clinical trials

Explore recruiting classic hodgkin lymphoma clinical trials.

Recruiting classic hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Classic Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Classic Hodgkin Lymphoma trials by city

Classic Hodgkin Lymphoma clinical trials

Recruiting classic hodgkin lymphoma studies right now

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Also recruiting in Europe

PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma

A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

Classic Hodgkin Lymphoma trials by city

Other conditions